Altimmune, Inc. (ALT) Financial Statements (2025 and earlier)

Company Profile

Business Address 910 CLOPPER ROAD
GAITHERSBURG, MD 20878
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments131,891197,815184,880190,301215,92337,240
Cash and cash equivalent36,926135,117111,097190,301115,9188,963
Short-term investments 94,96562,69873,783 100,00628,277
Restricted cash and investments424134343434
Receivables  1001734,02912,3731,650
Other undisclosed current assets5,32111,6707,7269,7621,927470
Total current assets:137,254209,626192,813204,126230,25739,395
Noncurrent Assets
Operating lease, right-of-use asset     904698
Property, plant and equipment4136511,0811,4481,0571,104
Intangible assets, net (including goodwill)   12,41912,41912,82412,732
Intangible assets, net (excluding goodwill)   12,41912,41912,82412,732
Other noncurrent assets1,63936361587273129
Total noncurrent assets:2,0521,01414,11514,73914,85814,663
TOTAL ASSETS:139,306210,640206,928218,865245,11554,058
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,7465,8028,0354,74412,0203,923
Employee-related liabilities2,313  
Accounts payable2112,0704,8042,03461218
Accrued liabilities3,5353,7323,23139611,4083,905
Business combination, contingent consideration, liability    6,090  
Other undisclosed current liabilities6,7226,3419,0197,442  
Total current liabilities:10,46812,14317,05418,27612,0203,923
Noncurrent Liabilities
Long-term debt and lease obligation  4,5811,4541,8281,865
Long-term debt, excluding current maturities  4,5811,4541,8281,865
Liabilities, other than long-term debt1,424215  5,3902,750
Other liabilities2240    
Operating lease, liability 1,402175    
Business combination, contingent consideration, liability     5,3902,750
Other undisclosed noncurrent liabilities 3,9064,183    
Total noncurrent liabilities:5,3304,3984,5811,4547,2184,615
Total liabilities:15,79816,54121,63519,73019,2398,538
Equity
Equity, attributable to parent123,508194,099185,293199,135225,87645,520
Common stock775442
Additional paid in capital689,864665,427568,399497,342417,338187,915
Accumulated other comprehensive loss(4,973)(5,004)(5,227)(5,040)(5,045)(5,020)
Accumulated deficit(561,390)(466,331)(377,884)(293,171)(186,421)(137,376)
Total equity:123,508194,099185,293199,135225,87645,520
TOTAL LIABILITIES AND EQUITY:139,306210,640206,928218,865245,11554,058

Income Statement (P&L) ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues20426(68)4,4108,1855,801
Gross profit:20426(68)4,4108,1855,801
Operating expenses(103,192)(96,355)(87,672)(101,324)(62,984)(27,266)
Operating loss:(103,172)(95,929)(87,740)(96,914)(54,799)(21,465)
Nonoperating income (expense)8,1137,4822,830(177)337886
Investment income, nonoperating8,0747,3512,870203323843
Other nonoperating income (expense)48166(32)(374)2415
Interest and debt expense(9)(35)(8)(6)(9)(2)
Loss from continuing operations before equity method investments, income taxes:(95,068)(88,482)(84,918)(97,096)(54,471)(20,581)
Other undisclosed income from continuing operations before income taxes9358692
Loss from continuing operations before income taxes:(95,059)(88,447)(84,910)(97,091)(54,462)(20,579)
Income tax benefit  197 5,41759
Loss from continuing operations:(95,059)(88,447)(84,713)(97,091)(49,044)(20,520)
Loss before gain (loss) on sale of properties:(97,091)(49,044)(20,520)
Other undisclosed net loss      
Net loss:(95,059)(88,447)(84,713)(97,091)(49,044)(20,520)
Other undisclosed net income attributable to parent      
Net loss attributable to parent:(95,059)(88,447)(84,713)(97,091)(49,044)(20,520)
Preferred stock dividends and other adjustments      (453)
Net loss available to common stockholders, diluted:(95,059)(88,447)(84,713)(97,091)(49,044)(20,973)

Comprehensive Income ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(95,059)(88,447)(84,713)(97,091)(49,044)(20,520)
Other undisclosed comprehensive income (loss)31223(187)4(24)20
Comprehensive loss, net of tax, attributable to parent:(95,028)(88,224)(84,900)(97,086)(49,069)(20,500)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: